Shared Care Thyroid Cancer Follow-up Utilizing Thyroid Cancer Assessment Reminder System (TCARS) Study - A Pilot Study.
Recruiting now NCT05510934
Run by Nova Scotia Health Authority · for 18 and older · All sexes
What this study is about
This study aims to assess the feasibility of a shared-care model for low-risk differentiated thyroid cancer (DTC) patients, primary care practitioners (PCPs) and the tertiary care center utilizing a digital health-based thyroid cancer assessment reminder system (TCARS) in Medable with an expedited referral to specialists for rapid assessment in case of a concern of recurrence.
Who can join (things the study team will check)
✅ You may be able to join if…
- AJCC stage 1 DTC with no radiological or biochemical evidence of thyroid cancer with undetectable high sensitivity serum thyroglobulin (hsTG <0.06 mcg/L*);
- Anti-thyroglobulin antibody (anti-TG AB <20 IU/ml*);
- Thyroid ultrasound scan [USS] negative for regional recurrence at least 24 months after most recent treatment;
- AJCC stage 2 DTC with no radiological or biochemical evidence of cancer (undetectable hsTG and anti-TG AB and negative thyroid USS) at least 48 months after most recent treatment
- Patient is comfortable with using the mobile or Medable application and has access to internet.
Where this trial is running
- Nova Scotia Health, Halifax, Nova Scotia, Canada
Who to contact
Syed A. Imran, Dr. · 902-473-2952 · Ali.Imran@nshealth.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05510934.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.